Seon Mi Kim

No ORCID on file · 3 papers in corpus · active 2015-2026

Study types

  • article 2
  • other 1

Condition tags

  • endometriosis 2
other 2026
Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist
Clinical pharmacokinetics ·doi:10.1007/s40262-025-01595-0

Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/ph…

article 2020
First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women
The Journal of clinical endocrinology and metabolism ·doi:10.1210/clinem/dgaa939

OBJECTIVE: To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TU2670, a novel orally active, nonpeptide gonadotropin-releasing hormone (GnRH) antagonist administered to healthy female participants. METHODS: This…

article 2015
Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic–pituitary–gonadal axis
Life sciences ·doi:10.1016/j.lfs.2015.08.016

AimsSuppression of the hypothalamic-pituitary-gonadal axis has been widely utilized for the management of gonadal-hormone-dependent diseases such as endometriosis. Efforts to develop orally available gonadotropin-releasing hormone (GnRH) an…